Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Priority claimed from PCT/EP2002/010194external-prioritypatent/WO2003022282A1/en
Publication of MXPA04002407ApublicationCriticalpatent/MXPA04002407A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Patients suffering from renal carcinoma are treated with a 4-pyridylmethyl-phthalazine anti-angiogenesis agents. Patients having different tumor types, e.g. renal cancer, are treated with a 4-pyridylmethyl-phthalazine anti-angiogenesis agent while undergoing chemotherapy.
MXPA04002407A2001-09-122002-09-11Use of 4-pyridylmethylphthalazines for cancer treatment.
MXPA04002407A
(en)